Guide
Compounded Semaglutide 3-Month Plans: The Middle Term, Priced
Month-to-month is $165, three months $149, six months $147 and twelve months $145 — a $240 saving over a year, about 12%. The prepayment also commits you through titratio
Month-to-month is $165, three months $149, six months $147 and twelve months $145 — a $240 saving over a year, about 12%. The prepayment also commits you through titration, which is when roughly 7% of STEP-1 participants discontinued for an adverse event.
Is a prepaid plan worth it?
| Term | Monthly | Plan total | Saving vs monthly | Paid |
|---|---|---|---|---|
| Month-to-month | $165 | — | — | Monthly. Cancel before the next cycle |
| 3-month | $149 | $447 | $48 | Up front |
| 6-month | $147 | $882 | $108 | Up front |
| 12-month | $145 | $1,740 | $240 | Up front |
The twelve-month plan saves $240 against paying monthly — about 12%. It also commits you before the period in which discontinuation usually happens: roughly 7% of STEP-1 participants stopped for an adverse event, and that occurs during titration.
Ask what is refunded if you stop, and separately what happens to a prepaid balance if supply is interrupted. The FDA proposed excluding semaglutide from the 503B bulks list on 30 April 2026 and that is unresolved.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Which protocols did you capture, and at what price?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $165 | $149 | $147 | $145 | $1,740 |
| Microdose | $129 | $117 | $114 | $110 | $1,320 |
| Sublingual ODT | $199 | $185 | $177 | $165 | $1,980 |
Flat at every covered dose within each protocol, stated on the provider's own plan pages. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
What is the salt-form question?
Its sodium and acetate salts are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing. Tirzepatide has no equivalent of this question.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Compounded Semaglutide 3-Month Plans?
Month-to-month is $165, three months $149, six months $147 and twelve months $145 — a $240 saving over a year, about 12%. The prepayment also commits you through titration, which is when roughly 7% of STEP-1 participants discontinued for an adverse e
Which figures did you read yourselves?
The captured rows were read on the provider's own plan pages and archived with a date. Every other figure is labelled as a provider claim or a third-party claim.
Does the price change as the dose increases?
On dose-tiered programmes, yes. The programmes we captured are flat across the full 0.25 to 2.4 mg range, so the advertised figure is also the maintenance figure.
What is the salt-form question?
Semaglutide sodium and acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Compounded Tirzepatide Online: Legal, Safety and Cost GuidePillar / Money
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Mochi Health vs Henry MedsComparisons
- Zepbound vs Compounded TirzepatidePillar / Money
- Zepbound vs Compounded TirzepatideComparisons
- Ro Body vs Mochi HealthComparisons
- NexLife vs Ro BodyComparisons
Related coverage
- What Is Actually in a Compounded GLP-1: Additives, Salt Forms and a Chemistry Problem
- Semaglutide providers compared
- Cheapest semaglutide online
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Trimi vs Zappy Health
- TrimRx vs WeightWatchers Clinic
- TrimRx vs Yucca Health
- TrimRx vs Zappy Health
Semaglutide Ranked. “Compounded Semaglutide 3-Month Plans: The Middle Term, Priced.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/compounded-semaglutide-3-month-plan-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.